

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on April 24, 2009.

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. § 121
Patent Application
Docket No. INN.133

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Marianne Dibrino
Art Unit : 1646
Applicants : Alessandro Moretta, Mariella Della Chiesa
Serial No. : 10/563,045
Filed : December 30, 2005
Conf. No. : 6062
For : Compositions and Methods for Regulating NK Cell Activity

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

ELECTION UNDER 35 U.S.C. § 121
AND SUPPLEMENTAL PRELIMINARY AMENDMENT

Sir:

Applicants request that the period for response be extended one month through and including April 24, 2009, the fees for which have been paid at the time this Election was filed.

In response to the written Restriction Requirement dated February 24, 2009 in the above-identified patent application, Applicants hereby elect to prosecute the invention of Group I (claims 56-59), without traverse. As the species, Applicants hereby elect DF200 as the species of the isolated antibody; IL-2 as the additional component; a detectable moiety; and the KIR receptors bind to KIR2DL1 and KIR2DL2/3 and neutralizes KIR mediated inhibition of NK cell cytotoxicity.

Prior to examination, Applicants respectfully request that the subject application be amended as follows: